Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| If you look at some of the other studies where they go from forced to allowing physicians and patients to more individualized titration, it improves dramatically tolerability |
| And our presence in global primary care over a long time position us well for that |
| We have strong skills in modified release and have brought many drugs into the market, and that makes me encouraged to believe that we can address the once a day challenge we put in front of us in a good manner, and look forward to get that data and review them and prepare for next step |
| But also, cachexia with an aging population and chronic diseases, we think there's a big opportunity to improve long-term outcome for patients |
| In the PCV, we have also introduced new conjugation chemistry, a new generation of chemistry that allow you to get stronger, better immunogens and antibody responses |
| And many regimens today, even those with the immuno-oncology product, contain chemo backbone, and this will improve the ability to stand through treatment and be in a better performance status |
| And we think it will be by itself improving long-term outcomes, and we'll make patients more fit for treatment |
| And as the trial from the event trial came, we thought this brings us an opportunity to take the best what we learned in the first and incorporate with new technology to have what we think could be a best-in-class and a first flu-COVID combo vaccine |
| So I think it can be a really nice improvement for the 2025 season when we hope to have it possibly approved in the US and worldwide |
| So we feel, because of the improvement, very positive about being able now to generate immune data that's strong for the 2A and the B that will be used |
| The first generation showed that the mRNA platform when used properly can be very powerful as it was an event trial that we said was superior to standard of care |
| And of course, we recently shared two season data that will be published with -- which looked really good, strong |
| It was very strong, very much |
| And otherwise, we have the -- in addition to RSV, the modFlu data, the Phase III trial that's ongoing that is also reading out this year, and it's also in the younger adult population that we think will benefit from combination vaccine to vaccinate frequently for flu, they vaccinate less frequently for COVID, which by combining the two, we think will improve public health and hopefully bring it to similar level that you see for the older adults |
| And we believe that area will be a very significant growth for us |
| Of course, if outcomes contains more than antibody immune levels, but we have made some improvement, we formulated it and now been able to show in Phase II that we have very robust immune response, not just to A, but also to B, although B is increasingly less common |
| So while we defend it vigorously, we also have added growth drivers in bacterial vaccines, among them C |
| It's a safe, efficacious drug |
| It's a very convenient administrated antibody, and it has performed really well in clinical studies |
| difficile, where we have made some great progress and look forward to see that drive bacterial vaccines to new heights |
| But we only want to give you those examples on how we continuously advance our tech platform and that we believe we can improve immune response against old serotypes to get them more effective and add more serotypes |
| It's one of our many interesting opportunities |
| Of course they relies on multiple pillars and contain already well-established franchises that we expand |
| And based on principle that has been validated by injectable in this area, why do we think that's really attractive? Well, it's approaching 1 billion patients worldwide that suffer from obesity |
| But what are the other two? Mikael Dolsten The second is another GLP-1 that has some different features also in the clinic and looks encouraging when it comes to PK and dose |
| We're already moving a fourth-generation conjugate vaccines that will contain more serotype and also improved technology forward |
| We've seen in pediatric sector that you improve vaccination rates when you come with combination vaccines |
| And that brings what we think a new generation that can be very powerful and can be explored for infant and adults |
| So we also thought it could be to our advantage to have more than one GLP and be able to combine them with other oral drugs that I spoke about |
| And what we see is that we can retain the good antibody response for COVID |
| Statement |
|---|
| You also see it in COPD, which include that some of the muscles involved in breathing is becoming poor because of weight loss |
| GDF-15 turns out to be a major factor driving a kind of sickness field and also catabolic metabolist, which means that you are losing weight, you have a poor appetite, poor nutrition status |
| What about safety? Danu's biggest problem was nausea, vomiting |
| The aging population start also to have cachexia as a major problem, limiting their lifespan as they're past 75 |
| Too much weight loss leads to muscle impairment |
| And it's a growing population that will be a burden on health care and their own well-being |
| And on immune response, our levels against B was lower than standard of care |
Please consider a small donation if you think this website provides you with relevant information